Drug intelligence / Profile preview

Pipeline 2

Development stage: Preclinical
Lead developer: ImmunoDesigners
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

Pipeline 2 is an early-stage molecular glue degrader (MGD) being developed by ImmunoDesigners for multiple indications. The drug is designed to induce the targeted protein degradation of New Target 2, an anonymized scaffold protein that plays a critical role in regulating cell division and cytokinesis. By acting as a molecular glue, Pipeline 2 facilitates the interaction between New Target 2 and an E3 ubiquitin ligase, leading to the target's ubiquitination and subsequent proteasomal degradation. The program is currently in the hit-to-lead stage of preclinical development.

Beyond the preview

Go deeper on Pipeline 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pipeline 2.

Explore the full profile